TipRanks on MSN
Pfizer’s Phase 3 Study on Dazukibart: A Potential Game-Changer for Muscle Disorders
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A PHASE 3, ...
An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in disease activity in adults with dermatomyositis, a randomized phase II study showed.
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Although the strongest predictor of malignancy in dermatomyositis is age, all adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback